Fate Therapeutics
FATE
156 hedge funds and large institutions have $1.68B invested in Fate Therapeutics in 2020 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 45 increasing their positions, 57 reducing their positions, and 25 closing their positions.
144% more call options, than puts
Call options by funds: $11.7M | Put options by funds: $4.79M
44% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 25
19% more capital invested
Capital invested by funds: $1.41B → $1.68B (+$267M)
6% more funds holding
Funds holding: 147 → 156 (+9)
4.05% more ownership
Funds ownership: 95.52% → 99.57% (+4%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
21% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 57
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$83.1M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$47.8M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$37.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$36M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$36.5M |
| 2 |
Millennium Management
New York
|
-$19.6M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$19.1M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$16.9M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$15.5M |
FATE Hedge Fund Activity: Q1 2020 in Review
156 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q1 2020, worth a combined $1.68B — up 19% from $1.41B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new FATE positions and 25 closed out — a net gain of 11 holders — while 45 added to existing stakes and 57 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $83.1M. The largest seller was Ameriprise, cutting an estimated $36.5M.
- 156 institutional investors held Fate Therapeutics (FATE) as of Q1 2020, up from 147 in Q4 2019.
- Funds reported $1.68B of Fate Therapeutics stock for Q1 2020, up 19% quarter-over-quarter.
- 36 funds opened new Fate Therapeutics positions in Q1 2020 and 25 closed out, a net change of +11 holders.
- The largest Fate Therapeutics buyer in Q1 2020 was Janus Henderson Group, an estimated $83.1M added.
- The largest Fate Therapeutics seller in Q1 2020 was Ameriprise, an estimated $36.5M sold.
Based on aggregated 13F filings for Q1 2020.